GLOBUS MEDICAL INC

Current report

Tariff policies and potential countermeasures could increase our costs and disrupt our global supply chain, which could negatively impact the results of our operations.

Current report

In April 2025, the U.S. began enacting the imposition of widespread and substantial tariffs on imports, with plans for additional tariffs to potentially be adopted in the future. We are unable to predict what additional actions, if any, may ultimately be taken by the U.S. or other governments with respect to tariffs or trade relations, which products may be subject to such actions (including subject to U.S. export control restrictions), or what actions may be taken by any other countries in retaliation, or the impact, if any, that any such policy changes could have on our business. The potential resultant impact of the imposition of these or any other new or increased tariffs on import markets could have an adverse effect on Globus’ results of operations, cash flow and financial condition.

Current report

Risks Relating to the Nevro Merger

Current report

Integrating the Nevro business into Globus may be more difficult, costly or time-consuming than expected and Globus may fail to realize the anticipated benefits of the Nevro Merger, which may adversely affect our business results and negatively affect the value of our common stock.

Current report

We have incurred and expect to incur non-recurring costs associated with the acquisition of Nevro, as well as transaction fees and other costs related to the Nevro Merger. Such costs include, among others, legal, accounting, investment banking and consulting fees.

Current report

The success of the Nevro Merger will depend on, among other things, our ability to realize the anticipated benefits, synergies and efficiencies from integrating the Nevro business into Globus. If we are not able to successfully integrate Nevro’s business into Globus within the anticipated time frame, or at all, the anticipated synergies, efficiencies and other benefits of the Nevro Merger may not be realized fully, or at all, or may take longer to realize than expected. In addition, Globus may incur additional or unexpected costs in order to realize these benefits. Failure to achieve the expected synergies could significantly reduce the expected benefits associated with the Nevro Merger.

Current report

An inability to realize the full extent of the anticipated benefits of the Nevro Merger, as well as any delays encountered in the integration process, could have an adverse effect upon the revenues, level of expenses and operating results of Globus, which may adversely affect the value of our common stock.

Current report

The Company may also incur restructuring and integration costs in connection with the Nevro Merger. There are processes, policies, procedures, operations, technologies and systems that must be integrated in connection with the Nevro Merger and the integration of Nevro’s business into Globus. Although Globus expects that the elimination of duplicative costs, strategic benefits and additional income, as well as the realization of other efficiencies related to the integration of the businesses, may offset incremental transaction, merger-related and restructuring costs over time, any net benefit may not be achieved in the near term or at all. While

Current report

Globus has assumed that certain expenses would be incurred in connection with the Nevro Merger, there are many factors beyond Globus’s control that could affect the total amount or the timing of the integration and implementation expenses.